Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, IncisionFree, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy
By Dr Sangeetha Rao Author’s note:Dr Sangeetha Rao, an Ophthalmologist and new member of the Keratoconus Self-Help and Support Group, shares her reflections from the
University of Liverpool researchers receive £2.4 million to advance a minimally invasive treatment for keratoconus, aiming to improve patient access and reduce NHS costs Researchers
The National Institute for Health and Care Research (NIHR) have awarded Dr. Shafi Balal a prestigious Doctoral Fellowship at University College London (UCL). The NIHR Doctoral Fellowship
Keratoconus (KC) doesn’t just affect your vision – it can also impact your daily life and emotional well-being. Distorted eyesight from KC can interfere with
ABDO have made us “Charity of the Month”. You can read their article here
Investigator Initiated, Prospective Study of Xenia Corneal Lenticule This information is provided directly by researchers and we recognise that it isn’t always easy to understand.
It is with great sadness that we announce the death of Mike Oliver, co-founder of the Keratoconus Group, long time trustee and ex Chair of
University of Liverpool biomedical engineer, Dr. Ahmed Abass, had been awarded funding from Fight for Sight and Keratoconus Group UK to develop a new type of spectacle lens
The Medical Research Council (MRC) has awarded Cardiff University’s School of Optometry and Vision Sciences a grant valued at £2.4 million for a large scale
